Oncology

News

Dizal breaks new ground for EGFR drugs in lung cancer

Dizal's Zegfrovy has taken the oral EGFR inhibitor class into new territory, with a phase 3 win as a frontline treatment for a form of lung cancer.

News

Kidney biotech R1's $78m debut, and other biofinancings

Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.

News

Magnifying glass held by a human hand over a group of paper people cutouts in different colours

Denying prostate cancer screening 'no longer rational'

A German study has stoked debate about the merits of screening for prostate cancer, which is lagging behind breast cancer screening in Europe.

News

AZ piles pressure on MSD et al in gastric cancer

AstraZeneca's cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage gastric cancer.

News

Yellow balloons with smiling faces drawn on them in black ink

J&J says Inlexzo follow-up 'promising' in bladder cancer

Johnson & Johnson says localised delivery of its FGFR inhibitor erdafitinib could provide the first targeted treatment for early‑stage bladder cancer.

News

Immutep investors spooked by LAG-3 failure in lung cancer

Friday the 13th has turned into a horror story for Immutep, whose share price has collapsed after it abandoned a pivotal trial of its LAG-3 drug efti.

Dizal breaks new ground for EGFR drugs in lung cancer

Kidney biotech R1's $78m debut, and other biofinancings

Denying prostate cancer screening 'no longer rational'

AZ piles pressure on MSD et al in gastric cancer

J&J says Inlexzo follow-up 'promising' in bladder cancer

Immutep investors spooked by LAG-3 failure in lung cancer

As patents expire, fampridine is cleared for NHS use in MS

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks